AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen

OCALA, Fla., Jan. 29, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a sponsorship agreement with the Centre for Human Drug Research (CHDR) for the proposed AMP-COV-100 (CHDR2049) clinical study on the safety of AIMs drug Ampligen as an intranasal therapy, a critical step in the companys ongoing efforts to develop Ampligen as a COVID-19 treatment.